These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37950153)

  • 1. High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy.
    Dong Y; Zheng M; Wang X; Yu C; Qin T; Shen X
    BMC Cancer; 2023 Nov; 23(1):1097. PubMed ID: 37950153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer.
    Zhu C; Wang S; Du Y; Dai Y; Huai Q; Li X; Du Y; Dai H; Yuan W; Yin S; Wang H
    BMC Gastroenterol; 2022 Oct; 22(1):437. PubMed ID: 36253721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumors.
    Zhang D; Wang T; Zhou Y; Zhang X
    Medicine (Baltimore); 2023 Apr; 102(14):e33468. PubMed ID: 37026918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Profiling Identifies
    Shi J; Bao M; Wang W; Wu X; Li Y; Zhao C; Liu W
    Front Immunol; 2021; 12():722807. PubMed ID: 34646265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1.
    Noh JY; Lee IP; Han NR; Kim M; Min YK; Lee SY; Yun SH; Kim SI; Park T; Chung H; Park D; Lee CH
    Cell Mol Gastroenterol Hepatol; 2022; 14(4):769-788. PubMed ID: 35843546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of transient receptor potential channels-related signature for prognosis, tumor immune microenvironment, and treatment response of colorectal cancer.
    Wang L; Chen X; Zhang H; Hong L; Wang J; Shao L; Chen G; Wu J
    Front Immunol; 2022; 13():1014834. PubMed ID: 36389750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
    Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of a novel signature as a diagnostic and prognostic biomarker in colorectal cancer.
    Wang D; Liufu J; Yang Q; Dai S; Wang J; Xie B
    Biol Direct; 2022 Nov; 17(1):29. PubMed ID: 36319976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer.
    Li YY; Wang XY; Li Y; Wang XM; Liao J; Wang YZ; Hong H; Yi W; Chen J
    Cell Oncol (Dordr); 2023 Jun; 46(3):777-791. PubMed ID: 36920728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer.
    Kuai W; Xu X; Yan J; Zhao W; Li Y; Wang B; Yuan N; Li Z; Jia Y
    Biomed Res Int; 2020; 2020():5294043. PubMed ID: 32509862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children.
    Ruan Y; Xie L; Zou A
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10841-10850. PubMed ID: 37314514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma.
    Liang Z; Sun R; Tu P; Liang Y; Liang L; Liu F; Bian Y; Yin G; Zhao F; Jiang M; Gu J; Tang D
    Front Immunol; 2022; 13():944286. PubMed ID: 36591255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LOXL1 promotes tumor cell malignancy and restricts CD8 + T cell infiltration in colorectal cancer.
    Li C; Chen S; Fang X; Du Y; Guan XY; Lin R; Xu L; Lan P; Yan Q
    Cell Biol Toxicol; 2024 Jan; 40(1):6. PubMed ID: 38267662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer.
    Weixler B; Cremonesi E; Sorge R; Muraro MG; Delko T; Nebiker CA; Däster S; Governa V; Amicarella F; Soysal SD; Kettelhack C; von Holzen UW; Eppenberger-Castori S; Spagnoli GC; Oertli D; Iezzi G; Terracciano L; Tornillo L; Sconocchia G; Droeser RA
    Oncotarget; 2015 Nov; 6(35):37588-99. PubMed ID: 26439988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.